<code id='38097C9CDA'></code><style id='38097C9CDA'></style>
      • <acronym id='38097C9CDA'></acronym>
      <center id='38097C9CDA'><center id='38097C9CDA'><tfoot id='38097C9CDA'></tfoot></center><abbr id='38097C9CDA'><dir id='38097C9CDA'><tfoot id='38097C9CDA'></tfoot><noframes id='38097C9CDA'>
      • <optgroup id='38097C9CDA'><strike id='38097C9CDA'><sup id='38097C9CDA'></sup></strike><code id='38097C9CDA'></code></optgroup>
        5. <b id='38097C9CDA'><label id='38097C9CDA'><select id='38097C9CDA'><dt id='38097C9CDA'><span id='38097C9CDA'></span></dt></select></label></b><u id='38097C9CDA'></u>
          <i id='38097C9CDA'><strike id='38097C9CDA'><tt id='38097C9CDA'><pre id='38097C9CDA'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-10-04 07:22:03 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：3244
                                  
                                    
          
                                   
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH
          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.
          That sounds staggering to many patients — but it’s far less than analysts expected.
          advertisement
          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Sen. Bill Cassidy on how to lower drug prices
                                
                            
          Next article：  
                                      
                                          Malaria cases in Florida and Texas: Here’s what you need to know
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles